USPTO serial 98942613
JUNA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PURATH,ANICKA S
- Law office
- TMEG LAW OFFICE 101
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with JUNA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Seong-Cheol Son
Seong-Cheol Son Voyer Law134 Abbott Street, Suire 403Vancouver, BC, V6B2K4CanadaGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Home testing apparatus for diagnosing human medical conditions, namely, test strips for measuring blood glucose levels; Home testing apparatus for diagnosing human diseases, namely, test strips for measuring blood glucose levels; Home testing apparatus for diagnosing sexually transmitted diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV; Home testing apparatus for diagnosing sexually transmitted infections, namely diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV; Medical disease testing apparatus for home use, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, malaria; Medical disease testing apparatus for human medical conditions, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV and malaria; Medical disease testing apparatus for human diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV and malaria; Medical disease testing apparatus for sexually transmitted diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV; Medical disease testing apparatus for sexually transmitted infections, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV; Medical diagnostic testing apparatus for home use, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV and malaria; Medical diagnostic testing apparatus for human medical conditions, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV and malaria; Medical diagnostic testing apparatus for human diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV and malaria; Medical diagnostic testing apparatus for sexually transmitted diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of HIV; Medical diagnostic testing apparatus for sexually transmitted infections, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV; In vitro medical testing kits for home use, namely, ovulation test kits; In vitro medical testing kits for human medial conditions, namely ovulation test kits; In vitro medical testing kits for humans diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, malaria; In vitro medical testing kits for sexually transmitted diseases, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in HIV disease detection; In vitro medical testing kits for sexually transmitted infections, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, HIV | ACTIVE | Jan 30, 2023 |
| 044 | Telehealth care services; Mental health services; Health care services; Virtual health care services; Health care services, namely, health and wellness programs in the field of obesity; Health care services, namely, wellness programs; Health care services, namely, chronic care services; Health care services offered through a network of health care providers on a contract basis; Health care services in the field of sleeping disorders; Health care services in the field of sexual wellness; Health care services in the field of obesity; Providing health care via the internet; Providing health care via a website; Providing health care via a global computer network; Web-based health care services; Health care services, namely, integrated health care services with a network of health care providers; Providing information in the field of chronic health conditions via a website; Providing information in the field of general health and wellness via a website | ACTIVE | Jan 30, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 7, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 7, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 22, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 22, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 22, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 17, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 19, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 7, 2025 | NWAP | NEW APPLICATION ENTERED | — |